Epobis is a short peptide derived from structural motifs of erythropoietin (EPO), which is being studied in laboratory models mainly for its tissue-protective and anti-inflammatory effects without stimulating erythropoiesis. Attention is focused on neuroprotection, microcirculation and modulation of the immune response.

In laboratory studies, Epobis is associated with research in areas such as:

• neuroprotection and modulation of nociception,
• anti-inflammatory signaling and immunomodulation,
• microcirculation and endothelial function,
• tissue homeostasis and regeneration after stress,
• studies of peripheral neuropathy and metabolic stress.

What is Epobis?

Epobis is a peptide construct derived from selected regions of erythropoietin (EPO), designed to retain tissue-protective and anti-inflammatory properties without stimulating erythropoiesis. It is used in model systems to investigate neuronal and endothelial cytoprotection, to monitor microcirculation, and to follow immune signaling during metabolic or ischemic stress.

From a research perspective, it follows the concept of so-called "tissue-protective" EPO derivatives, which target non-hematopoietic receptors and map the pathways responsible for the cellular response to damage.

How does Epobis work?

The literature reports that EPO-derived peptides can activate the EPOR/CD131 receptor complex (often referred to as the “innate repair receptor”), which mediates JAK2/STAT and PI3K/Akt signals leading to cytoprotection, suppression of proinflammatory cytokines, and promotion of microvascular perfusion. Due to the different receptor selectivity, the hematopoietic activity typical of full-length EPO is not expected, allowing for targeted studies of tissue homeostasis and inflammation.

In the case of the powder form, a solution is prepared before the experiment and applied according to the protocol; in the case of parenteral application (sc or im), plasma profiles and biomarkers of tissue response are monitored.

Researched effects and interesting facts

• Anti-inflammatory signaling: cytokine modulation and reduction of NF-κB activation in tissue models.
• Endothelial protection: observed changes in vascular reactivity and microcirculation markers.
• Neuroprotection: monitoring neuronal survival and markers of synaptic integrity during oxidative/ischemic stress.
• Tissue regeneration: supporting cells in repairing and maintaining homeostasis after damage.
• Without erythropoietic activity: the design goal of EPO-derivatives is to investigate tissue protection without increasing hematocrit.

Dosage in studies

• Dose: Unspecified (titration protocols typically utilize low microgram ranges based on target and biomarkers).
• Form: subcutaneously or intramuscularly after preparation of solution from lyophilized powder.
• Frequency: Not specified (determined by study design and endpoints).
• Duration: Unspecified (short-term and longer protocols depending on the model).

Possible side effects (injectable form)

• local irritation, redness or tenderness at the injection site,
• transient hot flashes, headache or dizziness,
• rarely nausea; in sensitive individuals monitor blood pressure and comfort after application.

Resources

• Review papers on tissue-protective EPO derivatives (EPOR/CD131) and their anti-inflammatory mechanisms.
• Experimental studies evaluating neuroprotection, microcirculation, and endothelial function upon activation of JAK2/STAT and PI3K/Akt.
• Publications on EPO-mimetic peptides without erythropoietic activity in tissue and animal models.